Page 29 - Primary Biliary Cholangitis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Primary biliary cholangitis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Primary Biliary Cholangitis Today - Breaking & Trending Today

Rare Liver Disease Summit Seeks to Improve Patient Health Outcomes

/PRNewswire/ The American Liver Foundation (ALF) will bring together leading rare liver disease experts and clinicians, patients, caregivers, advocacy. ....

United States , Bruce Dimmig , Intrahepatic Cholestasis , Lorraine Stiehl , Theo Heller , Vertex Pharmaceuticals , Everylife Foundation For Rare Diseases , National Institutes Of Health , American Liver Foundation , Rare Liver Disease Summit , Chief Executive Officer , American Liver , Translational Hepatology Section , National Institutes , Acute Hepatic Porphyria , Alagille Syndrome , Biliary Atresia , Crigler Najjar Syndrome , Glycogen Storage Disease , Lysosomal Acid Lipase Deficiency , Primary Biliary Cholangitis , Primary Sclerosing Cholangitis , Progressive Familial Intrahepatic Cholestasis , Nodular Regenerative , Rare Liver Disease Patient Bill , Kostecki Family ,

Ascletis' Subcutaneous PD-L1 Antibody ASC22 Demonstrated Potential of Functional Cure of Chronic Hepatitis B as 42.9% of Patients with Baseline HBsAg100 IU/mL Obtained Sustained HBsAg Loss

Ascletis presented Phase IIb clinical trial results of subcutaneous PD-L1 antibody ASC22 for functional cure of CHB at oral session of EASL ILC 2022 on June 25, 2022, Beijing Time The Phase IIb clinical trial results further demonstrated the potential of ASC22+NAs treatment as a functional cure for CHB On-treatment ALT flares might be used as a predictor or monitor of patients' responses to the CHB treatment HANGZHOU, China and SHAOXING, China, June 27, 2022 /PRNewswire/ Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the latest Phase IIb clinical trial results of subcutaneous PD-L1 antibody ASC22 (Envafolimab) in patients with chronic hepatitis B (CHB) at an oral parallel session of the International Liver Congress 2022 (ILC 2022) held by the European Association for the Study of the Liver (EASL). The interim report is based on a randomized, single-blind, multi-center Phase IIb clinical trial to assess the efficacy and safety of ASC22 in treatment of CHB ....

United States , Hong Kong , Guiqiang Wang , Jinzij Wu , Hong Kong Stock Exchange , University First Hospital , Liver Disease Center , Infectious Diseases Department , Ascletis Pharma Inc , International Liver Congress , Ascletis Pharma , European Association , Week Four , Peking University First , Beijing Time , Chronic Hepatitisb Virus Infection , Scletis Presented Phase Iib Clinical Trial Results Of Subcutaneous Pd L1 Antibody Asc22 For Functional Cure Chb At Oral Session Easl Ilc 2022 On June 25 , Eijing Time The Phase Iib Clinical Trial Results Further Demonstrated Potential Of Asc22 Nas Treatment Asa Functional Cure For Chb On Alt Flares Might Be Used Predictor Or Monitor Patients 39 Responses To Hangzhou , Hina And Shaoxing , June 27 , 022 Prnewswire Ascletis Pharma Inc Hkex 1672 , Uot Ascletis Quot Today Announces The Latest Phase Iib Clinical Trial Results Of Subcutaneous Pd L1 Antibody Asc22 Envafolimab In Patients With Chronic Hepatitisb Chb At An Oral Parallel Session International Liver Congress 2022 Ilc Held By European Association For Study Easl Interim Report Is Based Ona Randomized , Ingle Blind , Ulti Center Phase Iib Clinical Trial To Assess The Efficacy And Safety Of Asc22 In Treatment Chb Patients Clinicaltrials Gov Identifier Nct04465890 1 0 Mg Kg Cohort , 5 Chb Patients Were Randomized To Be Treated With 1 0 Mg Kg Asc22n 60 Or Placebo Pbo , N 15 Once Every 2 Weeks Q2w Plus Nucleost Ide Analogs Nas For 24 Week And Then Followed Another The Following Sets Forth Key Findings From Phase Iib Clinical Study On Asc22 42 9 Patients With Baseline Hbsag 100 Iu Mln 7 Obtained Sustained Loss Alt Flares Were Observed 21 In Groupn 48 While None Pbo Group Had More Reduction Among Three ,

GSK to present new data from the B-Clear phase IIb trial for bepirovirsen in chronic hepatitis B at the International Liver Congress 2022

GSK plc will present 12 abstracts at the European Association for the Study of the Liver’s International Liver Congress 2022, taking place on June 22-26 in London. ....

United Kingdom , City Of , Vera Gielen , Jennifer Cremer , Fung Yuen , Fernando Carren , Helen Smith , Ahmed Nader , Chris Corsico , Martin Leivers , James Fettiplace , Drug Administration , European Medicines Agency , International Liver Congress , London United Kingdom , European Association , Late Breaker , Targeted Literature Review , Medical Specialties , Bile Acid , Cholestatic Pruritus , Clinical Medicine , Liver Cancer , Liver Disease , Liver Transplantation , Primary Biliary Cholangitis ,

Ascletis Announces Appointment of Mr. John P. Gargiulo, Former North America President and CEO of Daiichi Sankyo, as Chief Business Officer

HANGZHOU, China and SHAOXING, China, June 13, 2022 /PRNewswire/ Ascletis Pharma Inc. (HKEX: 1672, "Ascletis"), today announces the expansion of management team with appointment of Mr. John P. Gargiulo, former North America President and CEO of Daiichi Sankyo, as Chief Business Officer. Mr. John P. Gargiulo will lead Ascletis' corporate business development and alliance management in this new role and report to Dr. Jinzi J. Wu, PhD, Founder, Chairman and CEO of Ascletis. Mr. John P. Gargiulo has over 30 years of successful experience in marketing strategies, business integration and commercial operations in global pharma/biotech industry. He has held various senior positionswithincreasing responsibility for 18 years at Daiichi Sankyo, where he made a transformative contribution in driving Daiichi Sankyo's U.S. business from the very beginning to an established pharma when he served as North America President and CEO of Daiichi Sankyo. "John is a veteran in our i ....

United States , Hong Kong , Johnp Gargiulo , Jinzij Wu , Daiichi Sankyo , Fuqua School Of Business , Hong Kong Stock Exchange , Prnewswire Ascletis Pharma Inc , Ascletis Pharma Inc , Duke University , Boston College , North America President , Chief Business , Chief Business Officer , Fuqua Scholar , Fuqua School , Bachelor Degree , Hina And Shaoxing , June 13 , 022 Prnewswire Ascletis Pharma Inc Hkex 1672 , Uot Ascletis Quot , Oday Announces The Expansion Of Management Team With Appointment Mr Johnp Gargiulo , Ormer North America President And Ceo Of Daiichi Sankyo , S Chief Business Officer Mr Johnp Gargiulo Will Lead Ascletis 39 Corporate Development And Alliance Management In This New Role Report To Dr Jinzij Wu , Hairman And Ceo Of Ascletis Mr Johnp Gargiulo Has Over 30 Years Successful Experience In Marketing Strategies , Usiness Integration And Commercial Operations In Global Pharma Biotech Industry He Has Held Various Senior Positionswithincreasing Responsibility For 18 Years At Daiichi Sankyo ,

Gannex Announces U.S. FDA Clearance of Clinical Trial on FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis

ASC42 has completed Phase I trials in the U.S. and China. This approval from U.S. FDA enables Gannex to complete a critical drug-drug interaction (DDI) study to support upcoming Phase III trials in China, the U.S. and European Union Gannex expects to complete this DDI study at the beginning of Q4, 2022 Currently, Phase II clinical trial of FXR agonist ASC 42 in China is in progress. Gannex intends to start Phase III clinical trials in China, the U.S. and European Union after the completion of the Phase II clinical trial which is ongoing in China SHANGHAI, June 8, 2022 /PRNewswire/ Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) today announces that it has obtained the U.S. FDA clearance for itsdrug candidate, ASC42, to initiate a drug-drug interaction (DDI) study. This important DDI study is designed to provide more evidence to support upcoming Phase III clinical trials in China, the U.S. and European Union for treatment of primary biliary cholangitis (PBC). ....

United States , Hong Kong , Clin Gastroenterol Hepatol , Jinzij Wu , Prnewswire Gannex , Hong Kong Stock Exchange , European Union , Ascletis Pharma Inc , Ascletis Pharma , Obeticholic Acid , Primary Biliary Cholangitis , Reduced Mortality With Treatment , Biliary Cholangitis , American Association , Liver Diseases , Sc42 Has Completed Phasei Trials In The Us And China This Approval From Fda Enables Gannex To Completea Critical Drug Interaction Ddi Study Support Upcoming Phase Iii , He Us And European Union Gannex Expects To Complete This Ddi Study At The Beginning Of Q4 , 022 Currently , Hase Ii Clinical Trial Of Fxr Agonist Asc 42 In China Is Progress Gannex Intends To Start Phase Iii Trials , He Us And European Union After The Completion Of Phase Ii Clinical Trial Which Is Ongoing In China Shanghai , June 8 , 022 Prnewswire Gannex , A Wholly Owned Company Of Ascletis Pharma Inc Hkex 1672 Today Announces That It Has Obtained The Us Fda Clearance For Itsdrug Candidate , O Initiatea Drug Interaction Ddi Study This Important Is Designed To Provide More Evidence Support Upcoming Phase Iii Clinical Trials In China , He Us And European Union For Treatment Of Primary Biliary Cholangitis Pbc Asc42 Is An In House Developed , Ovel Non Steroidal ,